
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Chicago - Future advances in the management of patients with alopecia areata are expected to emerge from ongoing efforts aiming to facilitate clinical research studies and gain a better understanding of the immunological disease mechanisms and its genetic associations, Maria K. Hordinsky, M.D., said at Academy '03.






